Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer

Abstract

The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.

Get full access to this article

View all access options for this article.

References

National Comprehensive Cancer Network. NCCN breast cancer practiceguidelines v.1.2005. Available at:www.nccn.org.professionals/physician_gls/PDF/breast/pdf. Accessed on February 4, 2005.

Citron

M.L.

, Berry

D.A.

, Cirrincione

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of inter-group trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol. 2003; 21: 1431–1439.

Hudis

C.A.

, Schmitz

Dose-dense chemotherapy in breast cancer and lymphoma. Semin Oncol. 2004; 31(3 suppl 8):19–26.

Goldspiel

B.R.

Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma. Pharmacotherapy. 2004; 24: 1347–1357.

Ellis

G.K.

, Livingston

R.B.

, Gralow

J.R.

, Green

S.J.

, Thompson

Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol. 2002; 20: 3637–3643.

SWOG S0221. Phase III trial of continuous schedule AC + G vs. Q 2 week schedule AC, followed by paclitaxel given either every 2 weeks or weekly for 12 weeks as post-operative adjuvant therapy in node-positive or high-risk node negative breast cancer. Southwest Oncology Group. Available at: www.swog.org.Visitors/ViewProtcolDetails/asp/ProtocolID=1927. Accessed on February 4, 2005.

Hesketh

P.J.

, Kris

M.G.

, Grunberg

S.M.

Proposal for classifying the acuteemetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15: 103–109.

National Comprehensive Cancer Network. NCCN antiemesis practice guidelines v.1.2005. Available at: www.nccn.org.professionals/physician_gls/PDF/antiemesis.pdf. Accessed on February 4, 2005.

Stillwell

T.J.

, Benson

R.C.

Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer. 1988; 61: 451–457.

10.

Weiss

R.B.

Hypersensitivity reactions. Semin Oncol. 1992; 19: 458–477.

11.

Weiss

R.B.

, Donehower

R.C.

, Wiernik

P.H.

Hypersensitivity reactions from Taxol. J Clin Oncol. 1990; 8: 1263–1268.

12.

Bookman

M.A.

, Kloth

D.D.

, Kover

P.E.

Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Semin Oncol. 1997; 24(suppl 1): S19–13, S19–14, S19–15.

13.

Larson

D.L.

Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49: 1796–1799.

14.

Larson

D.L.

What is the appropriate management of tissue extravasation by antitumor agents?

Plast Reconstr Surg. 1985; 75: 397–405.

15.

Mullin

, Beckwith

M.C.

, Tyler

L.S.

Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000; 35: 57–74.

16.

Stein

M.E.

, Drumea

, Abu-Rasmi

Taxol-induced cellulitis after extravasation: a rarely reported event. Am J Clin Oncol. 1997; 20: 540.

17.

Bicher

, Levenback

, Burke

T.W.

Infusion site soft-tissue injury after paclitaxel administration. Cancer. 1995; 76: 116–120.

18.

Ajani

J.A.

, Dodd

L.G.

, Daugherty

Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst. 1994; 86: 51–53.

19.

Patterson

W.P.

, Reams

G.P.

Renal and electrolyte abnormalities due to chemotherapy. In: Perry

M.C.

, ed. The Chemotherapy Sourcebook. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494–504.

20.

King

P.D.

, Perry

M.C.

Hepatotoxicity of chemotherapy. Oncologist. 2001; 6: 162–176.